117077-93-7

Basic information

• Product Name: (2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE
• Synonyms: (2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE;4-dimethylamino-2,6-dichloropyrimidine;2,6-dichloro-N,N-diMethylpyriMidin-4-aMine
• CAS NO: 117077-93-7
• Molecular Formula: C6H7Cl2N3
• Molecular Weight: 192.05
• Mol File: 117077-93-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 113 °C
• Boiling Point: 306.1±22.0 °C(Predicted)
• Appearance: /
• Density: 1.393±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.58±0.10(Predicted)
• CAS DataBase Reference: (2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE(117077-93-7)
• EPA Substance Registry System: (2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE(117077-93-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 117077-93-7(Hazardous Substances Data)

Usage

General Description

(2,6-DICHLORO-PYRIMIDIN-4-YL)-DIMETHYL-AMINE is a chemical compound with the molecular formula C6H7Cl2N3. It is a member of the pyrimidine family, which is a class of organic compounds known for their use in pharmaceuticals and agrochemicals. This specific compound is a derivative of pyrimidine with two chlorine atoms attached to the 2 and 6 positions and a dimethylamine group attached to the 4 position. The compound has been studied for its potential applications in medicinal chemistry and organic synthesis, and it is also used as an intermediate in the production of various pharmaceuticals and agrochemicals. It is important to handle this compound with caution, as it may have hazardous properties and should only be used by trained professionals in a controlled laboratory setting.

Upstream product

• 10132-07-7 4-amino-2,6-dichloropyrimidine 
• 74-88-4 methyl iodide 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 681836-58-8 N₄-[2-(isopropylamino)-4-methylphenyl]-N₆,N₆-dimethyl-2-[4-(2-pyridinyl)-1-piperazinyl]-4,6-pyrimidinediamine 
• 117077-96-0 (4-benzyloxy-6-chloro-pyrimidin-2-yl)-dimethyl-amine 
• 117077-94-8 (6-benzyloxy-2-chloro-pyrimidin-4-yl)-dimethyl-amine 
• 1202-22-8 6-chloro-N₂,N₂,N₄,N₄-tetrapyrimidin-2,4-diamine 
• 771556-94-6 2-chloro-N,N,N',N'-tetramethyl-pyrimidine-4,6-diamine 

Relevant articles and documents

Isotopic exchange of hydrogen at C-5 in pyrimidine derivatives: tautomers with an sp3-hybridised C-5 carbon atom

The proton-to-deuterium exchange reaction of the hydrogen atom, at the 5-position of 1.5 pyrimidine derivatives has been studied, The exchange proceeds under both acidic and alkaline conditions, Under acidic conditions, the mechanism involves protonation

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson’s disease, epilepsy, and addiction.